Changing the tide
Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-resistant Tuberculosis in the WHO European Region 2011–2015

Dr Hans Kluge
Special Representative of the Regional Director on M/XDR-TB
Director, Division of Health Systems and Public Health

Dr Guenael Rodier
Director, Division of Communicable Diseases, Health Security and Environment

Dr Masoud Dara, Programme Manager, TB/MDR-TB and team
Outline of the presentation

• The tuberculosis (TB) and multidrug-resistant TB (MDR-TB) situation in the world and in the WHO European Region
• Key challenges in the prevention and control of multidrug- and extensively drug-resistant tuberculosis (M/XDR-TB)
• The Consolidated Action Plan to Prevent and Combat M/XDR-TB in a nutshell
• Regional initiatives
• The case of Azerbaijan
• The WHO Regional Committee for Europe resolution on M/XDR-TB
TB burden in the Region

- 420,000 cases estimated, 330,000 notified (5.6% of the global burden in 2009)
- 46,000 deaths due to TB
- Majority of TB patients (87%) and deaths (92%) from the 18 high-priority countries of the Region
- Highest case detection rate (78%) and lowest treatment success rate (70%) among all WHO regions
- HIV/TB prevalence 5.3%
- TB risk factors in Europe (population attributable fraction):
  - HIV: 6–15%
  - smoking: 21–29%
  - diabetes: 14–15%
  - alcohol: 14–35%

MDR-TB burden, European Region and the world

- 15 out of 27 high-MDR-TB burden countries in the WHO European Region (81,000 patients annually)
- In 2009, only 27,765 MDR-TB patients notified (1/3 of estimates) due to limited access to diagnosis
- Treatment success rate of MDR-TB cohort in the Region 57.4% only (global figures unknown)

Key challenges in prevention and control of M/XDR-TB

- Health system failure to prevent emergence and spread of drug-resistant TB
  - Late diagnosis of TB and M/XDR-TB
  - Inadequate treatment of TB and subsequent acquired resistance
  - Poor infection control and contact tracing

- Insufficient capacity to treat M/XDR-TB patients
  - Models of care not cost-effective, nor patient friendly
  - Difficult access to expensive second-line drugs
  - Lack of new medicines
What is new about the Action Plan?

- **Prompt diagnosis** including newly endorsed molecular diagnostic techniques
- **Equitable access** to adequate treatment
- **Health system approach** to MDR-TB prevention and control
- Emphasis on involvement of **civil society organizations**
- Identifying and addressing **social determinants**
- Working in **partnership**, twinning of cities/programmes
- Robust monitoring framework, **accountability and follow-up**
- **Facilitating development** of new drugs and tools
Overview of the Action Plan

Goal
• To contain the spread of drug-resistant TB by achieving universal access to prevention, diagnosis and treatment of M/XDR-TB in all Member States of the WHO European Region by 2015

Targets
• To decrease by 20 percentage points the proportion of MDR-TB among previously treated patients by end 2015
• To diagnose at least 85% of estimated MDR-TB patients by 2015
• To treat successfully at least 75% of patients estimated to be suffering from MDR-TB by 2015
Expected achievements of the Action Plan

- 225,000 MDR-TB patients diagnosed
- 127,000 MDR-TB patients treated successfully
- 250,000 MDR-TB cases averted
- 13,000 XDR-TB cases averted
- 120,000 lives and US$ 5 billion directly saved by treating M/XDR-TB
Areas of intervention

1. Prevent the development of M/XDR-TB
   • Identify and address social determinants, improve adherence to treatment, improve health financing and involved primary health care services

2. Scale up access to early diagnosis
   • Strengthen TB laboratory network, facilitate introduction of new diagnostic technologies, break system barriers to access

3. Scale up access to effective treatment
   • Ensure sufficient quantity of quality second line drugs, improve management of adverse reactions and promote production of new drugs

4. Scale up TB infection control
   • Assess, plan and improve airborne infection control in health care and congregate settings
Areas of intervention (cont.)

5. Strengthen surveillance
   - Electronic recording and reporting, improve quality of data and capacity to use data

6. Expand management capacity of the programmes
   - Adapt new policy guidance, improve human resources, foster partnership and coordination, ensure ethics and human rights

7. Address the needs of special populations
   - Ensure TB/HIV collaborative activities, specific action for children, prisoners, migrants and hard-to-reach populations
Regional initiatives

• Regional Green Light Committee
• Regional laboratory initiative
• TB technical assistance mechanism (TBTEAM)
• Partnership with the Global Fund
• Country assessment and trouble shooting in collaboration with partners, including European Centre for Disease Prevention and Control
• Cross-border TB initiative
• Steering group for the Action Plan and Berlin follow-up
Case of Azerbaijan

- Renewed commitment of Ministry of Health and new TB programme manager appointed
- Revision and approval of new national TB control policies and guidelines
- Parallel reporting system phased out
- Full access to first- and second-line drug susceptibility testing for all patients
- Embarking on countrywide implementation of GeneXpert rapid molecular diagnosis of TB and MDR-TB
- Full collaboration with the WHO Regional Office for Europe, the United States Agency for International Development, and other partners
- Preparation for making round 11 proposal to the Global Fund
WHO Regional Committee resolution on M/XDR-TB adopts the Consolidated Action Plan and urges Member States:

- to harmonize as appropriate their national health strategies and/or TB/MDR-TB response plans based on the Regional Plan
- to identify and address determinants and health system challenges leading to emergence of drug-resistant TB
- to provide universal access to early diagnosis and effective treatment of MDR-TB patients
- to address the needs of special populations
- to closely monitor and evaluate implementation of the actions outlined in the Action Plan

requests the Regional Director:

- to provide leadership, strategic direction and technical support for implementation of the Action Plan
- to facilitate the exchange of experiences and know-how among Member States
- to establish a platform to strengthen partnership for prevention and control of TB and M/XDR-TB
- to assess progress in the prevention and control of M/XDR-TB every other year starting from 2013 and report back to the Regional Committee
Thank you